Anxiety Disorders

Anxiety disorders include generalized anxiety disorder (GAD), panic disorder, social anxiety disorder, specific phobias, and agoraphobia. They are not nerves, not stress, not a personality trait. They are diagnosable conditions defined by persistent fear or worry that hijacks sleep, concentration, relationships, and the body itself. The National Survey of American Life (NSAL), the largest probability sample of Black Americans ever assembled for psychiatric epidemiology, reported a 12-month any-anxiety-disorder prevalence near 10 percent and a lifetime prevalence near 20 percent in African Americans (Himle et al., 2009, Journal of Anxiety Disorders, PMID 19231131). The headline finding from that work is uncomfortable: Black adults were at lower 12-month risk for GAD, panic, and social anxiety than non-Hispanic whites, but the Black adults who did meet criteria experienced greater symptom severity, greater functional impairment, and greater chronicity. The disorder is rarer in the data and worse in the body.

• Persistent worry or dread that is hard to control and shows up most days for at least six months (GAD)
• Sudden, peaking episodes of intense fear with a pounding heart, shortness of breath, chest pain, dizziness, sweating, numbness, or a sense of unreality, lasting around 10 minutes (panic attack)
• Avoiding places, crowds, transit, or being alone outside the home because of fear of having a panic attack (agoraphobia)
• Intense fear of being judged, embarrassed, or watched in social or performance situations (social anxiety disorder)
• Disproportionate fear of a specific trigger, animals, heights, blood, flying, needles, that drives avoidance (specific phobia)
• Physical signs: muscle tension, jaw clenching, tension headaches, low back pain, GI upset, frequent urination, fatigue
• Sleep disruption: difficulty falling asleep, mid-night waking, unrefreshing sleep
• Trouble concentrating, irritability, feeling on edge or keyed up
• Restlessness, inability to relax even in safe settings
• Increased use of alcohol, cannabis, or food to take the edge off

The standard primary-care screen is the GAD-7, a seven-item self-report developed and validated by Spitzer and colleagues (Archives of Internal Medicine, 2006, 166:1092, PMID 16717171). Scores of 5, 10, and 15 mark mild, moderate, and severe anxiety, with 10 the conventional threshold for further evaluation. The instrument is fast, free, and embedded in most electronic health records. It is also imperfect in Black patients. Parkerson and colleagues (Journal of Anxiety Disorders, 2015, PMID 25725310) showed differential item functioning by race: Black/African American respondents with the same underlying anxiety scored lower on the GAD-7 than white respondents, meaning the cutoff systematically misses Black patients with clinically significant anxiety. More recent work (Black and colleagues, 2025, PMID 40608458) replicated noninvariance findings across Black and white groups on the GAD-7 and PHQ-9. The clinical implication is direct: a Black patient with a GAD-7 of 7 or 8 deserves a real conversation, not a "normal" stamp, and a clinician who relies only on the cutoff will undercount. Pair the GAD-7 with direct questions about somatic symptoms, sleep, avoidance, and substance use, and screen for PTSD separately (the PCL-5), because NSAL found PTSD prevalence higher in Black adults than in white adults and the symptoms overlap with GAD.

Two treatments have the strongest evidence base across anxiety disorders, and they work about equally well: cognitive behavioral therapy (CBT) and SSRIs or SNRIs. The American Psychiatric Association practice guideline for panic disorder (2009, reaffirmed 2010) recommends CBT, an SSRI, an SNRI, or a tricyclic as first-line monotherapy, with patient preference and access driving the choice. NICE guidance for GAD and panic (CG113, updated through 2020) reaches the same conclusion. CBT for anxiety is structured, time-limited (typically 12 to 20 sessions), and targets the avoidance and catastrophic thinking that maintain the disorder; exposure-based variants are the active ingredient for panic, social anxiety, specific phobia, and agoraphobia. SSRIs (sertraline, escitalopram, paroxetine, fluoxetine) and SNRIs (venlafaxine, duloxetine) are the pharmacologic first-line, dosed up over four to six weeks, with full response typically taking 8 to 12 weeks. Buspirone is an option for GAD specifically.

Benzodiazepines (alprazolam, clonazepam, lorazepam, diazepam) are not first-line. They work fast, which makes them seductive in the visit, but they carry tolerance, physical dependence, withdrawal, cognitive impairment, fall risk, and overdose risk when combined with opioids or alcohol. The harms are not evenly distributed. Black patients are more likely to face benzodiazepine prescriptions in lieu of, rather than alongside, evidence-based psychotherapy, and the downstream consequences (dependence, ED visits, drug-related incarceration risk) hit harder. If a benzodiazepine is used, it should be short-term, defined-duration, and bridged to CBT or SSRI/SNRI, not a standing prescription.

Trauma-informed care matters here. Many Black patients carrying anxiety also carry racial trauma, community violence exposure, or police-related stress, and standard CBT manuals do not address those exposures by default. Ask for a clinician who has cultural competence training, who will not flinch when discrimination comes up in session, and who will not pathologize hypervigilance that is, in context, accurate.